Mark Cuban, co-founder of Cost Plus Drugs, and Linda Yaccarino, CEO of the employer GLP-1 platform eMed Population Health, were at SXSW drawing a contrast between their approach to GLP-1 drugs and that of other direct-to-consumer companies. They also announced a collaboration where Cost Plus Drugs will be one of eMed’s distribution partners.
The post At SXSW, Cuban and eMed CEO Draw Contrast Between Them and Other “Marketing” Companies appeared first on MedCity News.
When insider risk is a wellbeing issue, not just a disciplinary one
Written by Katie Barnett, Director of Cyber Security at Toro Solutions Insider risk is still often framed around intent, with the focus placed on malicious
